Alternatives to Fight Vancomycin-Resistant Staphylococci and Enterococci - Communication Bactérienne et Stratégie Anti-infectieuses Accéder directement au contenu
Article Dans Une Revue Antibiotics Année : 2021

Alternatives to Fight Vancomycin-Resistant Staphylococci and Enterococci

Benjamin Baëtz
Abdelhakim Boudrioua
  • Fonction : Auteur

Résumé

Gram positive pathogens are a significant cause of healthcare-associated infections, with Staphylococci and Enterococci being the most prevalent ones. Vancomycin, a last resort glycopeptide, is used to fight these bacteria but the emergence of resistance against this drug leaves some patients with few therapeutic options. To counter this issue, new generations of antibiotics have been developed but resistance has already been reported. In this article, we review the strategies in place or in development to counter vancomycin-resistant pathogens. First, an overview of traditional antimicrobials already on the market or in the preclinical or clinical pipeline used individually or in combination is summarized. The second part focuses on the non-traditional antimicrobials, such as antimicrobial peptides, bacteriophages and nanoparticles. The conclusion is that there is hitherto no substitute equivalent to vancomycin. However, promising strategies based on drugs with multiple mechanisms of action and treatments based on bacteriophages possibly combined with conventional antibiotics are hoped to provide treatment options for vancomycin-resistant Gram-positive pathogens.
Fichier principal
Vignette du fichier
antibiotics-10-01116.pdf (911.39 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04316670 , version 1 (08-04-2024)

Identifiants

Citer

Benjamin Baëtz, Abdelhakim Boudrioua, Axel Hartke, Caroline Giraud. Alternatives to Fight Vancomycin-Resistant Staphylococci and Enterococci. Antibiotics, 2021, 10 (9), pp.1116. ⟨10.3390/antibiotics10091116⟩. ⟨hal-04316670⟩
14 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More